Clinical Trial Update: A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

View source ↗

Summary

A recruiting clinical study assessing lisocabtagene maraleucel (Liso-cel) for relapsed/refractory follicular lymphoma in the post‑marketing setting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Liso-cel (lisocabtagene maraleucel)

Snippet

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Conditions: Follicular Lymphoma | Status: RECRUITING